vTv Therapeutics to Present at the 14th International Conference on Alzheimer’s & Parkinson’s Diseases
March 28 2019 - 4:30PM
Business Wire
Presentation of Results for Subgroup of
Patients with Mild Alzheimer’s Disease and Type 2 Diabetes in the
STEADFAST Study
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage
biopharmaceutical company engaged in the discovery and development
of orally administered treatments for Alzheimer’s disease and
diabetes, today announced that its Chief Scientific Officer,
Carmen Valcarce, will be presenting at the 14th International
Conference on Alzheimer’s & Parkinson’s Diseases held in
Lisbon, Portugal, March 26-31, 2019.
The presentation will describe the post-hoc analyses of MRI
brain volume measures, brain FDG-PET measures of glucose uptake and
plasma markers of inflammation in a subgroup of patients with type
2 diabetes, defined as having glycosylated hemoglobin (HbA1c)
greater than 6.5%, and mild Alzheimer’s disease in the azeliragon
Phase 3 study, STEADFAST.
The results support the hypothesis that treatment with
azeliragon may improve cognition and/or preserve function in
patients with type 2 diabetes and mild Alzheimer’s disease, showing
favorable trends for less whole brain atrophy, less ventricular
enlargement, and smaller decreases in glucose uptake in the
azeliragon-treated subgroup compared to placebo. Additionally, the
results from the inflammatory marker analyses revealed changes
consistent with RAGE inhibition, possibly indicating functional
pharmacologic activity of azeliragon in this subgroup of
patients.
Details of the presentations are below:
Abstract Number: ADPD9-2202
Abstract Title: Inflammatory
Biomarkers, Brain Volumetric MRI, FDG-PET Results in Patients with
Type 2 Diabetes in Azeliragon Phase 3 Trial in Mild Alzheimer’s
Disease
Saturday, March 30, PLENARY HALL - Auditorium
I, 17:15-19:15SYMPOSIUM 57: AD TREATMENT STRATEGIES
The data will be available on the Publications page of the
Company website following the presentation.
About Azeliragon
Azeliragon, also known as TTP488, is an orally active
small-molecule antagonist of RAGE. vTv Therapeutics discovered
and developed azeliragon using its proprietary drug discovery
platform, TTP Translational Technology®. A broad range of human
pathologic and experimental biologic investigation suggests that
RAGE ligand interactions lead to sustained inflammatory states that
play a role in chronic diseases such as diabetes, inflammation, and
AD.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical
company engaged in the discovery and development of orally
administered small molecule drug candidates to fill significant
unmet medical needs. vTv has a pipeline of clinical drug candidates
led by programs for the treatment of Alzheimer’s disease, diabetes,
and inflammatory disorders.
About STEADFAST
The STEADFAST study, two independent and identical randomized,
double-blind, placebo-controlled Phase 3 trials (Part A and Part
B), was designed to investigate the safety and efficacy of
azeliragon as a potential treatment for patients with mild
Alzheimer’s disease. The 18-month study targeted enrollment of 800
patients (400 in each trial). The first trial enrolled patients
in the United States and Canada who had a
clinical diagnosis of mild Alzheimer's disease and an MRI
consistent with this diagnosis. Enrollment of the second trial also
included study sites in the United
Kingdom, Ireland, Australia, New
Zealand and South Africa. In April 2018, results were
announced that the Part A Study failed to meet either co-primary
endpoint and clinical trials involving azeliragon, including the
Part B Study and the open-label extension study were terminated,
although the majority of patients in the Part B Study had at least
12 months’ worth of data at the time of closure. In June 2018,
topline efficacy results from the Part B Study were announced
showing that the study also failed to meet either of the co-primary
endpoints.
Forward-Looking Statements
This release contains forward-looking statements, which involve
risks and uncertainties. These forward-looking statements can be
identified by the use of forward-looking terminology, including the
terms “anticipate,” “believe,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and, in each case, their
negative or other various or comparable terminology. All statements
other than statements of historical facts contained in this
release, including statements regarding the timing of our clinical
trials, our strategy, future operations, future financial position,
future revenue, projected costs, prospects, plans, objectives of
management and expected market growth are forward-looking
statements. These statements involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Important factors that
could cause our results to vary from expectations include those
described under the heading “Risk Factors” in our Annual Report on
Form 10-K and our other filings with the SEC. These
forward-looking statements reflect our views with respect to future
events as of the date of this release and are based on assumptions
and subject to risks and uncertainties. Given these uncertainties,
you should not place undue reliance on these forward-looking
statements. These forward-looking statements represent our
estimates and assumptions only as of the date of this release and,
except as required by law, we undertake no obligation to update or
review publicly any forward-looking statements, whether as a result
of new information, future events or otherwise after the date of
this release. We anticipate that subsequent events and developments
will cause our views to change. Our forward-looking statements do
not reflect the potential impact of any future acquisitions,
merger, dispositions, joint ventures or investments we may
undertake. We qualify all of our forward-looking statements by
these cautionary statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190328005870/en/
Investors:vTv Therapeutics
Inc.IR@vtvtherapeutics.comorMedia:Josh
Vlasto212-572-5969PR@vtvtherapeutics.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Mar 2024 to Apr 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Apr 2023 to Apr 2024